Discovery of ((4R,5S)-5-Amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a Highly Potent, Selective, Orally Efficacious, and Safe Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Citations Over Time

Abstract

Dipeptidyl peptidase IV (DPP4) deactivates glucose-regulating hormones such as GLP-1 and GIP, thus, DPP4 inhibition has become a useful therapy for type 2 diabetes. Optimization of the high-throughput screening lead 6 led to the discovery of 25 (ABT-341), a highly potent, selective, and orally bioavailable DPP4 inhibitor. When dosed orally, 25 dose-dependently reduced glucose excursion in ZDF rats. Amide 25 is safe in a battery of in vitro and in vivo tests and may represent a new therapeutic agent for the treatment of type 2 diabetes.

Related Papers

• → Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism(2016)58 cited
• → Ameliorating effect of the novel dipeptidyl peptidase‐4 inhibitor teneligliptin on psoriasis: A report of two cases(2015)18 cited
• → K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent(2004)32 cited
• → The activity of dipeptidyl peptidase II and dipeptidyl peptidase IV in mice immunized with type II collagen(1992)
• → Synthesis of a Dipeptidyl Peptidase-4 Inhibitor(2014)